Skip to main content
  • Register
  • Help
  • Contact us

Anika Therapeutics Inc (ANIK) USD0.01

Sell:$41.98 Buy:$42.11 Change: $1.20 (2.94%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $1.20 (2.94%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
Change: $1.20 (2.94%)
Market closed |  Prices as at close on 7 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Anika Therapeutics, Inc. is a joint preservation company. The Company creates and delivers advancements in early intervention orthopedic care. It partners with physicians and develops minimally invasive products. It focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies. Its product categories include joint pain management therapies, orthopedic joint preservation and restoration care, and other. The joint pain management therapies offer injectable viscosupplement products that provide pain relief from osteoarthritis conditions and its products include MONOVISC, ORTHOVISC, CINGAL and HYVISC. The Company's orthopedic joint preservation and restoration care products include HYALOFAST and TACTOSET. It also offers a line of surgical implant and instrumentation solutions that are used by surgeons to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease.

Contact details

32 Wiggins Ave
United States
+1 (781) 4579000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$595.21 million
Shares in issue:
14.37 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Cheryl Blanchard
    President, Chief Executive Officer, Director
  • Michael Levitz
    Chief Financial Officer, Executive Vice President, Treasurer
  • David Colleran
    Executive Vice President, General Counsel, Secretary
  • Thomas Finnerty
    Executive Vice President of Human Resources
  • James Loerop
    Executive Vice President - Business Development and Strategic Planning

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.